M&A Deal Summary |
|
|---|---|
| Date | 2013-09-30 |
| Target | GSK s Arixtra Fraxiparine brands |
| Sector | Medical Products |
| Buyer(s) | Aspen Global |
| Sellers(s) | GSK |
| Deal Type | Divestiture |
| Deal Value | 700M GBP |
SEARCH BY
Try For Free 7-Day Free Trial
South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. Aspen has production capabilities for a wide variety of product types including tablets, capsules, eye drops, injectable products (including lyophilized vials), oral contraceptives, form-filled seals, suppositories, liquids, creams, ointments, infant nutritional products, and specialist active pharmaceutical ingredients.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United Kingdom) | 1 of 1 |
| Year (2013) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-02-28 |
OTC Products
Grand Bay, Mauritius OTC Products are primarily sold through the mass retail channel and include the Herron® range of analgesics, vitamins and supplements. This basket of products is expected to generate at least $20 million in annual revenue. |
Sell | $51M |
| Category | Company |
|---|---|
| Founded | 1715 |
| Sector | Life Science |
| Employees | 70,212 |
| Revenue | 30.3B GBP (2023) |
GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 12 of 24 |
| Sector (Medical Products) | 1 of 2 |
| Type (Divestiture) | 12 of 23 |
| Country (United Kingdom) | 5 of 13 |
| Year (2013) | 3 of 4 |
| Size (of disclosed) | 1 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-09-30 |
GlaxoSmithKline - Arixtra & Fraxiparine/Fraxodi Brands
United Kingdom GlaxoSmithKline - Arixtra & Fraxiparine/Fraxodi Brands is a specialised sterile production site which manufactures the Brands at Notre Dame de Bondeville, France . Arixtra and Fraxiparine/Fraxodi are made at a sterile site and the ability to manufacture steriles is globally recognised as a specialist activity resulting in limited possible competition. This is a factor further underlined by the increased complexity of the manufacturing process of Fraxiparine/Fraxodi due to the biological nature of the active pharmaceutical ingredients (“API”) used in their production. |
Sell | £700M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-12-03 |
Sirtris Pharmaceuticals
Cambridge, Massachusetts, United States Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with ageing, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction by activation of sirtuins, a recently discovered class of enzymes that the Company believes control the ageing process. |
Sell | - |
